Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$23.55 USD
-2.19 (-8.51%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $23.53 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.55 USD
-2.19 (-8.51%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $23.53 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
What's in the Cards for Celldex (CLDX) this Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
Why Is Celldex (CLDX) Down 27% Since the Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex's Immuno-Oncology Pipeline Continues to Impress
by Zacks Equity Research
On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).
Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate
Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store?
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) is expected to report first-quarter 2017 results on May 4. Celldex's performance has been encouraging with a three-quarter average positive surprise of 8.06%.
What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?
by Zacks Equity Research
GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.
Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?
by Zacks Equity Research
We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens.
What's in Store for Biogen (BIIB) this Earnings Season?
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.
Why Is Celldex (CLDX) Down 4.4% Since the Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.
Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Spectrum Pharmaceuticals, Inc. (SPPI) reported a loss of 22 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 26 cents but substantially wider than year-ago loss of 6 cents.
Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.